Wederom goed nieuws:
Published: 07:00 CEST 10-06-2016 /GlobeNewswire /Source: argenx N.V. / : ARGX /ISIN: NL0010832176
argenx announces presentation of updated ARGX-110 phase 1 data in TCL at EHA 2016
Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced the presentation of efficacy and safety data from its Phase 1 expansion study of ARGX-110 in patients with T-cell lymphoma (TCL) during an e-poster session at the European Hematology Association (EHA) Annual Congress (Copenhagen, Denmark).
The data from the Phase 1 expansion study show evidence of clinical and/or biological anti-tumor activity with ARGX-110 in highly refractory cutaneous TCL & peripheral TCL patients with confirmed overexpression of CD70. The abstract can be accessed here.
"The data presented today during EHA 2016 are very encouraging and further support the important role of CD70 in the TCL patient population. We are seeing signs of biological activity in both CTCL and PTCL patients that have failed standard therapy, as well as favourable safety profiles, so we are eager to present the full data set later this year in this critical indication," said Tim van Hauwermeiren, Chief Executive Officer of argenx. "We remain on track with patient recruitment, which we expect to complete by mid 2016."